Losartan May Improve Ovarian Cancer Treatment, Study Finds

Losartan May Improve Ovarian Cancer Treatment, Study Finds
Losartan, a medicine used for treating high blood pressure, might improve ovarian cancer treatment by making it easier for chemotherapy drugs to get to tumor cells, a study found. Patients with advanced ovarian cancer receiving losartan or other similar angiotensin signaling inhibitors lived a median 30 months longer on standard of care than those receiving other high blood pressure medicines. The study, "Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma," was published in PNAS. It might seem obvious that for anticancer drugs to work, they need to get to tumors, but getting from the point where the drug is administered — for example, into the bloodstream through an intravenous drip — into the actual tumor can be a challenge. This is especially true because tumors tend to have poor blood flow and dense matrices of protein in the space between cells. The researchers predicted that these barriers might be overcome with treatment targeting the angiotensin system, which helps control blood pressure, among other things. The compound losartan — approved in the U.S. for high blood pressure — showed promise for increasing the delivery of anticancer drugs to pancreatic tumors via this same mechanism. So the researchers wondered whether losartan might also be useful for enhancing treatment in ovarian cancer. Using mouse models of ovarian cancer, the researchers determined that losartan t
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *